Mark A. Mintun, MD
Vice-President of Pain and Neurodegeneration, Eli Lilly and Company
President of Avid Radiopharmaceuticals, Inc.
Dr. Mintun assumed the role of Vice-President of Pain Research and Neurodegeneration at Eli Lilly & Co in 2018. Dr. Mintun joined Lilly by way of Avid Radiopharmaceuticals, now a wholly-owned subsidiary of Eli Lilly & Co., when he became Chief Medical Officer at Avid in 2010 and then its President in 2014. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of Radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine, with joint appointments in Psychiatry, Neurology, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a BS in Chemical Engineering from the Massachusetts Institute of Technology in 1977, received his medical degree in 1981 at Washington University School of Medicine and completed a research fellowship in neurology and residency training in nuclear medicine. Dr. Mintun has co-authored over 200 research publications that include reports of brain imaging to characterize flow/metabolism relationships, neurotransmitter systems, circuitry for processing affective stimuli and the pathology of neurodegenerative diseases.